Health Canada has revealed updated and new draft guidance documents relating to medical devices. This move comes as part of the agency’s initiative to enhance the regulation surrounding machine learning-enabled medical devices (MLMD).
As reported, Health Canada opened consultation on this draft pre-market guidance for MLMD on August 30, 2023. These medical devices use machine learning in whole or part to fulfil their intended medical purpose. The guidance serves to assist manufacturers who submit an application for an MLMD, by outlining expectations for demonstrating the safety of such devices.
As machine learning technologies grow more complex and become integrated into the health care system, there is significant pressure on regulatory frameworks to evolve. This new draft guidance can be seen as part of a broader effort to keep policies up-to-date with the latest developments in the field.
Several crucial points manufacturers should note from the new guidance include:
- The manufacturer’s quality management system should effectively manage adaptable algorithms.
- The relevant clinical, non-clinical and mitigation information should be thoroughly included in the device description.
- The risk management and hazard analysis should focus on the ML/AL algorithm.
- There ought to be a robust assessment of the device’s performance, including possible biases in its decision-making.
This initiative by Health Canada aims to facilitate the safe integration of these advanced technologies into the health care system, thereby improving patient care and outcomes.
Manufacturers with interests in machine learning-enabled medical devices are strongly advised to review the new draft guidance and adjust their operations accordingly to meet the outlined expectations.